Open Access

Stereotactic radiosurgery for brain metastasis from gynecological malignancies

  • Authors:
    • Ekkehard Kasper
    • Franziska Ippen
    • Eric Wong
    • Eric Uhlmann
    • Scott Floyd
    • Anand Mahadevan
  • View Affiliations

  • Published online on: January 18, 2017     https://doi.org/10.3892/ol.2017.5621
  • Pages: 1525-1528
  • Copyright: © Kasper et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Brain metastases are relatively uncommon in gynecological malignancies, and there is limited available data on their management. The present study reports the outcomes of patients with brain metastasis from gynecological malignancies who were treated with stereotactic radiosurgery (SRS). Patients with brain metastasis from a gynecological primary site were treated with SRS using the Cyberknife™ frameless SRS system. Primary lesions were treated with a single fraction of 16‑22 Gy. A total of 3 resection cavities were treated with 8 Gy 3 times, meaning a total of 24 Gy, and 1 recurrent lesion was re‑irradiated with 5 Gy 5 times, meaning a total of 25 Gy. All patients were followed up with regular magnetic resonance imaging and clinical examinations 1 month after treatment and every 2 months thereafter. A total of 20 lesions in 8 patients were included in this study; 1 patient presented with metastatic endometrial cancer and the remaining 7 presented with metastatic ovarian cancer. The median age was 61 years (range, 48‑78 years). All patients had received systemic therapy prior to developing brain metastasis. A total of 3 patients underwent surgical resection and 1 patient was administered re‑irradiation for recurrence. There were 3 local failures in 2 patients. The actuarial 1‑, 2‑ and 3‑year local control rates were 91, 91 and 76%, respectively. The median overall survival time was 29 months. No SRS‑associated toxicities or neurological mortalities were observed. In conclusion, brain metastasis from gynecological malignancies is uncommon, however, SRS is a safe and effective treatment modality for local control as a primary or adjuvant treatment in patients with this disease.
View Figures
View References

Related Articles

Journal Cover

March-2017
Volume 13 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kasper E, Ippen F, Wong E, Uhlmann E, Floyd S and Mahadevan A: Stereotactic radiosurgery for brain metastasis from gynecological malignancies. Oncol Lett 13: 1525-1528, 2017.
APA
Kasper, E., Ippen, F., Wong, E., Uhlmann, E., Floyd, S., & Mahadevan, A. (2017). Stereotactic radiosurgery for brain metastasis from gynecological malignancies. Oncology Letters, 13, 1525-1528. https://doi.org/10.3892/ol.2017.5621
MLA
Kasper, E., Ippen, F., Wong, E., Uhlmann, E., Floyd, S., Mahadevan, A."Stereotactic radiosurgery for brain metastasis from gynecological malignancies". Oncology Letters 13.3 (2017): 1525-1528.
Chicago
Kasper, E., Ippen, F., Wong, E., Uhlmann, E., Floyd, S., Mahadevan, A."Stereotactic radiosurgery for brain metastasis from gynecological malignancies". Oncology Letters 13, no. 3 (2017): 1525-1528. https://doi.org/10.3892/ol.2017.5621